Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 2Thoracic 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Brain Neoplasms 92Glioblastoma 79Glioma 74Neuroblastoma 30Neoplasms 21Neurofibromatosis 1 20Astrocytoma 20Central Nervous System Neoplasms 19Sarcoma 17Melanoma 17Medulloblastoma 17Ependymoma 17Carcinoma, Non-Small-Cell Lung 15Meningioma 14Rhabdoid Tumor 13Osteosarcoma 13Wilms Tumor 12Sarcoma, Ewing 12Rhabdomyosarcoma 12Breast Neoplasms 12Neurofibroma, Plexiform 11Hepatoblastoma 11Neuroectodermal Tumors, Primitive, Peripheral 9Lymphoma, Non-Hodgkin 9Lung Neoplasms 9Histiocytosis, Langerhans-Cell 9Diffuse Intrinsic Pontine Glioma 9Recurrence 8Pheochromocytoma 8Pancreatic Neoplasms 8

Interventions

cabozantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Alveolar Soft Part × CNS × 30 days × Clear all
NCT02867592 2026-06-11

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
109 enrolled 24 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡